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Abstract (no less than 200 words) 
Pim-3 is a member of Provirus integration site for Moloney murine leukemia virus (Pim) 
family proteins that exhibits serine/threonine kinase activity. Similar to other Pim kinases 
(Pim-1 and Pim-2), Pim-3 is involved in many cellular processes including cell 
proliferation, survival, and protein synthesis. Although Pim-3 is expressed in normal 
vital organs, it is overexpressed particularly in tumor tissues of endoderm-derived organs 
including the liver, pancreas, and colon. Silencing of Pim-3 expression can retard in vitro 
cell proliferation of hepatocellular, pancreatic, and colon carcinoma cell lines, by 
promoting cell apoptosis. Pim-3 lacks any regulatory domains similarly as Pim-1 and 
Pim-2 do, and therefore, Pim-3 can exhibit its kinase activity once it is expressed. Pim-3 
expression is regulated at transcriptional and post-transcriptional levels, by transcription 
factors such as Ets-1 and post translational modifiers such as translationally controlled 
tumor protein (TCTP), respectively. Pim-3 could promote growth and angiogenesis of 
human pancreatic cancer cells in vivo in an orthotopic nude mouse model. Furthermore, a 
Pim-3 kinase inhibitor inhibited cell proliferation when human pancreatic cancer cells 
were injected into nude mice, without inducing any major adverse effects. Thus, Pim-3 
kinase may serve as a novel molecular target for developing targeting drugs against 
pancreatic and other types of cancer. 
Key words: Serine/threonine kinase; Pancreatic cancer; Ets-1; Translationally Controlled 
Tumor Protein; c-Myc; Vascular endothelium growth factor; Apoptosis; Cell cycle 
Core tip: The present review describes the advanced knowledge on the roles of Pim-3 in 
pancreatic cancer development and progression, and provides a new idea for Pim-3 as a 
therapeutic target in human pancreatic cancer. 
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1. Introduction 
Pancreatic cancer is the fourth leading cause of cancer related deaths in the USA [1], 
Patients usually suffer from non-specific abdominal discomforts in the primary stages, 
which often delay early diagnosis and treatment. Furthermore, even in the initial 
evolutionary phase of disease development, pancreatic cancer cells tend to undergo 
invasion and metastasis. Therefore, complete removal of tumors by surgical procedures 
is often impossible. Another major stumbling block in treating pancreatic cancer is its 
frequent resistance to the treatments of chemotherapy and radiotherapy. Consequently, 
pancreatic cancer has an exceptionally poor prognosis with an overall 5-year survival 
rate of less than 5% [2, 3]. Thus, a novel molecular targeted therapy will be a required 
therapeutic option for human pancreatic cancer treatment. 
 Malignant lesions of the pancreas show a ductal, an acinar, or an endocrine lineage. 
Nearly 80 % of pancreatic carcinomas are classified as pancreatic ductal adenocarcinoma 
(PDAC) [4]. An activating mutation in a key proto-oncogene, K-ras, has been observed in 
most PDACs and is presumed to be the first significant event involved in pancreatic 
carcinogenesis [4]. The development and progression of PDAC are associated with 
additional multiple genetic and epigenetic alterations in several proto-oncogenes, 
tumor-suppressor genes, and signaling pathways. Pim-3 kinase has essential roles in the 
regulation of signal transduction cascades. Moreover, its expression is enhanced in 
human pancreatic cancer cell lines and blocking of its expression induced apoptosis and 
decreased chemoresistance in human pancreatic cancer[5, 6]. 
Provirus integration site for Moloney murine leukemia virus (Pim) family is a 
proto-oncogene, which belongs to the group of calcium/calmodulin-regulated kinase and 
exhibits serine/threonine kinase activity [7]. The Pim family consists of three members, 
Pim-1, Pim-2, and Pim-3 [8]. The Pim-1 gene was first discovered as a proviral insertion 
site in Moloney murine leukemia virus [9]. A subsequent study demonstrated that Pim-1 
transgenic mice are predisposed to the development of experimental T cell lymphoma in 
cooperation with c-Myc and N-Myc [10]. Pim-2 was similarly identified as a proviral 
integration site in Moloney murine leukemia virus-induced T cell lymphomas [11] and can 
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synergize with c-Myc-induced lymphomagenesis [8]. Pim-3 was first identified as a novel 
gene, which is induced by membrane depolarization or forskolin in rat PC12 
pheochromocytoma cells, and was designated as kinase induced by depolarization 
(KID-1) [12]. Subsequently, KID-1 was renamed Pim-3 due to its high sequence similarity 
with other Pim family proteins, Pim-1 and Pim-2. Although Pim-3 can be detected in 
several normal tissues including those of the brain and heart, it is expressed in high 
levels in tumor tissues of various organs particularly those of endoderm-derived organs 
such as the pancreas, liver, colon and stomach [5, 13, 14]. 
In this review, we aim to highlight the pathophysiological roles of Pim-3 in the 
development and progression of cancer, particularly pancreatic cancer. Moreover, by 
considering the sequence similarity of Pim-3 with other Pim kinases, we were able to 
rationalize and predict the possible functions of Pim-3 by extrapolating from the data 
established for other Pim family members, particularly Pim-1. We further discuss the 
potential of Pim-3 as a novel molecular target for antineoplastic therapy.  
  
2. Structure of Pim-3 protein 
The open reading frame of human Pim-3 mRNA encodes a protein consisting of 326 
amino acids with a calculated molecular weight of 35,861 (Figure 1) [13]. Human Pim-3 
protein shares a high percentage of sequence homology with other members of the Pim 
family; Pim-3 and Pim-1 are 71% identical at the amino acid level, and Pim-3 and Pim-2 
are 44.0% identical [14-17]. 
The crystal structure of the Pim-3 protein has not yet been established, but several 
research groups have independently reported the crystal structure of Pim-1 and Pim-2 in 
the free form as well as in complex with their inhibitors [18-22]. The Pim-1 kinase adopts a 
two-lobe kinase fold connected by a hinge region (residues 121–126) [18]. The N-terminal 
lobe is composed of antiparallel β-sheets while the C-terminal lobe is composed mainly 
of α-helices (Figure 1). The adenosine triphosphate (ATP)-binding site is located in a 
deep intervening cleft between the two lobes and the hinge region. The Pim family 
proteins have no regulatory domains. Moreover, the ATP binding pocket in Pim-1 
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remains open irrespective of the presence or the absence of ATP [18], indicating a 
continuous maintenance of an active state conformation. Similar findings have been 
reported for the structure of Pim-2 kinase [20]. Thus, this may account for a good 
correlation between protein expression levels and overall kinase activity in the case of 
Pim-1 and Pim-2 [15]. Given a high sequence similarity (Figure 1 and NCBI Reference 
Sequence: NP_001001852.2), it is highly likely that Pim-3 kinase can adopt a similar 
three dimensional active conformation. Importantly, several residues believed to confer 
specificity in Pim-1 kinase are also conserved within Pim-2 and Pim-3 proteins.  
  
3. Mechanisms underlying control of Pim-3 expression 
Pim-3 mRNA is detected in several normal human tissues including the heart, brain, 
lung, kidney, spleen, placenta, skeletal muscle, and peripheral blood leukocytes, but not 
in colon, thymus, liver, and small intestine [13]. Pim-3 is expressed in endothelial cells [23]. 
Focal cerebral ischemia enhances Pim-3 mRNA expression in the peri-infarction cortex 
at early time points [24]. Similarly, ischemia reperfusion injury enhances intra-cardiac 
Pim-3 expression through p38-mediated signaling pathway [25]. In the mouse embryo, 
Pim-3 gene expression is detected in the liver, kidneys, lungs, thymus, central nervous 
system, periphery of the pancreas, secretory epithelium of the stomach and intestinal 
epithelium [26]. 
Pim-3 mRNA is found to be expressed in a panel of human Ewing’s family tumor cell 
lines [27] and nasopharyngeal carcinoma cell lines [28]. Likewise, we revealed that Pim-3 
protein is scarcely detected in adult normal endoderm-derived organs such as liver, 
pancreas, colon, and stomach, but its expression is augmented in premalignant and 
malignant lesions of these organs (Table 1) [5, 13, 29, 30]. Pim-3 protein is mostly detected 
in the cytoplasm of these tumors. In the liver, aberrant expression of Pim-3 protein is also 
observed in the precancerous lesions such as regenerative nodules and adenomatous 
hyperplasia [13]. Similarly, in the colon and the stomach, Pim-3 protein is detected at 
higher levels in adenoma tissues compared with adenocarcinoma tissues [29, 30]. These 
observations suggest that Pim-3 plays a crucial role in the initial phase of carcinogenesis. 
Li 6 
Pim-3 expression is regulated mainly at transcriptional and post-transcriptional 
levels. We will discuss the regulatory mechanisms at these two levels in detail. 
 
3.1. Transcriptional regulation of Pim-3 expression 
The EWS/Ets fusion proteins are pathognomonic for Ewing’s sarcoma (EWS). 
These fusion proteins arise from the chromosomal translocations that combine a portion 
of the amino-terminal region of EWS to one of the five members of Ets family 
transcription factors, friend leukemia integration transcription factor (FLI), Ets-related 
gene (ERG), FEV, Ets translocation variant 1 (ETV1), Ets translocation variant 4 
(ETV4/E1AF) [31]. Deneen and colleagues demonstrated that EWS/Ets fusion proteins 
can enhance Pim-3 gene transcription [27] in NIH 3T3 cells. 
We have determined the 5′-flanking region of the human Pim-3 gene, in order to 
elucidate the molecular mechanisms underlying constitutive Pim-3 expression in human 
pancreatic cancer cells. The human Pim-3 gene contains a canonical TATA box and 
putative binding sites for several known transcription factors, such as signal transducer 
and activator of transcription (Stat)3, Sp1, Ets-1, and nuclear factor NF-κB and NF-1 [32]. 
Pim-3 expression is enhanced in murine embryonic stem cells by leukemia inhibitory 
factor (LIF)/gp130-dependent signaling and the Stat3 transcription factor [33]. In contrast, 
the transfection of dominant negative form of Stat3 failed to inhibit the promoter activity 
of Pim-3 gene in human pancreatic cancer cells [32]. We further demonstrated that the 
region between −264 and −164 bp is essential for constitutive Pim-3 gene expression. This 
region contains one NF-κB, two Sp1, and two Ets-1 binding sites. Pim-1 gene can be 
induced by CD40-mediated signaling in an NF-κB-dependent manner [34]. However, the 
mutation in NF-κB binding site of the Pim-3 gene failed to reduce promoter activities in 
human pancreatic cancer cells [32]. Further examination has revealed that two Sp1 binding 
sites and the distal Ets binding site are crucial for the constitutive Pim-3 gene expression 
in human pancreatic cancer cells. The crucial roles of Ets-1 in constitutive Pim-3 gene 
expression are further supported by our observations that the overexpression of Ets-1 
enhances Pim-3 expression, whereas the transfection of dominant negative form of Ets-1 
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or Ets-1 small interfering RNA (siRNA) reduces Pim-3 expression in human pancreatic 
cancer cells [32]. As the expression of both Ets-1 and Sp1 is enhanced in various types of 
cancer, including pancreatic cancer [35, 36], Ets-1 and Sp1 may act cooperatively to induce 
constitutive Pim-3 gene expression as observed with their other target genes [37]. 
 
3.2. Post-transcriptional regulation of Pim-3 expression 
Pim kinase mRNAs have multiple copies of AUUUA sequences in their 3′ untranslated 
regions (UTR), a typical characteristic sequence of mRNA with a short half-life. 
Moreover, GC-rich sequences are present in the 5′ UTR of Pim mRNAs and frequently 
require cap-dependent translation. Indeed, the overexpression of eukaryotic translation 
initiation factor 4E (eIF4E) leads to an increase in Pim-1 protein levels, indicating that 
Pim-1 mRNA is translated in a cap-dependent manner [38]. Moreover, eukaryotic 
translation initiation factor, eIF4E, can bind a stem-loop-pair sequence present in the 3′ 
UTR of Pim-1 mRNA, which allows nuclear export and translation of Pim-1 transcript 
[39]. Since Pim-3 mRNA shows analogous sequences as Pim-1 mRNA, the translation of 
Pim-3 mRNA can be regulated in a similar way. 
Similar to Pim-1, Pim-3 can autophosphorylate some of their serine residues but 
whether this has any functional significance is yet to be elusive [19] . Moreover, Pim-1 and 
Pim-3 have been shown to bind to the serine/threonine protein phosphatase 2A (PP2A), 
resulting in their dephosphorylation, ubiquitination, and proteasomal degradation[40, 41] .  
3′UTR of Pim-1 harbors multiple binding sites for miRNAs including miRNA-33 
[42] , miRNA-16 [43] , miRNA-1 [44] , miRNA-328 [45] , and miRNA-210 [46] . The miRNAs 
are generally highly conserved evolutionarily. [42]  They can bind to the putative target 
sites present in 3′UTR of Pim-1 gene and can directly inhibit its expression at the 
post-transcriptional level, thereby blocking proliferation and growth of cancer cells and 
smooth muscle cells. The relevant analysis for the structure of human Pim-3 mRNA 
indicates that 3’ UTR of Pim-3 gene harbors multiple binding sites for miRNAs 
(www.ebi.ac.uk; www.microrna.org). It will be interesting to know whether Pim-3 
translation can be regulated in a similar manner. 
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We have identified a translationally controlled tumor protein (TCTP/TPT1) that 
interacts with Pim-3 by using yeast two-hybrid screening [47]. TCTP was aberrantly 
expressed and co-localized with Pim-3 in human pancreatic cancer cells. Mapping 
studies have confirmed that the co-localization is due to the interaction between the 
amino acids in the C-terminal fold of Pim-3 and the amino acids in the N-terminal 
sequence of TCTP. Pim-3 had no effect on TCTP expression or phosphorylation; however, 
overexpression of TCTP increased Pim-3 expression in a dose-dependent manner. 
Moreover, RNAi-mediated ablation of TCTP expression reduced Pim-3 protein but not 
mRNA via ubiquitin-proteasome degradation pathway. The resultant reduced Pim-3 
expression eventually inhibited tumor growth in vitro and in vivo by arresting cell cycle 
progression and enhancing apoptosis. Furthermore, TCTP and Pim-3 expression were 
significantly correlated in pancreatic adenocarcinoma specimens, and in tumors from 
patients showing high expression levels of TCTP and Pim-3 obtained at an advanced 
stage of cancer. Thus, TCTP-mediated enhancement of Pim-3 protein expression may be 
involved in the regulation of cell cycle progression and apoptosis in pancreatic 
carcinogenesis [47]. 
 
4. Biological functions of Pim-3 
Treatment with Pim-3 shRNA can decrease in vitro proliferation of various types 
of cancer cells by inducing apoptosis [5, 13, 29]. The major function of Bad, a pro-apoptotic 
BH3-only protein, is to regulate apoptosis. Unphosphorylated Bad binds and eventually 
inactivates anti-apoptotic family members, primarily Bcl-XL and also Bcl-2. 
Phosphorylation of Bad at Ser112, Ser136, and Ser155 impairs its binding to Bcl-XL and 
Bc1-2 and the translocation of Bad from the surface of mitochondria to the cytosol is 
guided by the protein 14-3-3. The presence of unbound Bc1-XL maintains a 
mitochondrial membrane potential and inhibits apoptosis [48, 49]. Pim-1 and Pim-2 can 
phosphorylate Bad at Ser112, while Akt phosphorylates Ser136 and Ser155. The 
phosphorylation of Bad can result in its inactivation and subsequent inhibition of 
apoptosis [50, 51]. Elevated levels of Pim-3 increases the amount of Bad phosphorylated at 
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Ser112 and inhibits apoptosis, while Pim-3 shRNA treatment dephosphorylates Ser112 and 
promotes apoptosis (Figure 2) [5, 29]. Therefore, similar to Akt and other Pim kinases, 
Pim-3 can modulate apoptosis by phosphorylating the pro-apoptotic molecule, Bad. 
Moreover, Pim-3 gene transduction increased Bcl-2 expression, suppressed apoptosis as 
evidenced by reduced caspase-3 activation, and eventually protected against hepatic 
failure in D-galactosamine-sensitized rats, which received lipopolysaccharide [52]. 
Similarly, the transfection of Pim-3 gene into cardiomyocytes attenuated 
ischemia/reperfusion injury-induced cell death through a p38 mediated MAPK signaling 
pathway [25]. Erythropoietin can protect renal cells from apoptosis by activating Stat5 and 
this anti-apoptotic effect is also mediated by Pim-3 [53]. 
Pim-3 shows a high sequence identity with Pim-1 even at their kinase domains 
(Figure 1). Both Pim-1 and Pim-3 bind to a consensus peptide substrate 
(AKRRRRHPSGPPTA) with a remarkable high affinity (Kd = 40–60 nM), whereas the 
binding affinity of this peptide for Pim-2 is relatively weak (640 nM) [19]. Therefore, 
Pim-1 and Pim-3 can phosphorylate the same or a similar set of substrates, and the 
evaluation of Pim-1 characteristics and functions can provide useful insights to decipher 
the major biological functions of Pim-3. In addition to Bad, Pim kinases can 
phosphorylate a wide range of cellular proteins. These include transcription factors (Stat 
[54], c-Myc [55], Myb [56], runt-related transcription factor (Runx) 1 and Runx3), cell cycle 
regulators (p21CIP and p27KIP1, Cdc25A, and Cdc25C), signaling pathway intermediates 
(suppressor of cytokine signaling 1 (SOCS1) [57], SOCS3 [58], and MAP3K5 [59]), and 
regulators of protein synthesis (eukaryotic translation initiation factor 4B (eIF4B))[60]. 
Pim-1 can phosphorylate Cdc25A, thereby increasing its phosphatase activity 
and the activity of cyclin D1-associated kinases, which can result in cell cycle 
progression [61]. Pim-1 phosphorylates Cdc25C-associated kinase 1 (C-TAK1), which can 
potently inhibit Cdc25C and can promote cell cycle progression at the G2/M phase [62]. 
Pim-1 can phosphorylate the threonine residue of p21, another molecule involved in cell 
cycle progression. Its phosphorylation leads to its relocation to the cytoplasm resulting in 
enhanced protein stability and eventually increased cell proliferation [63, 64]. All Pim 
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kinases including Pim-3 can phosphorylate CDK inhibitor, p27 at its threonine residues, 
thereby inducing the binding of p27 to 14-3-3 protein, resulting in its nuclear export and 
proteasome-dependent degradation [65]. Moreover, Pim-1 phosphorylates and inactivates 
forkhead transcription factors, FoxO1a and FoxO3a, resulting in depressed p27 gene 
transcription, which leads to cell cycle progression (Figure 2) [65]. Similarly, the 
transfection with Pim-3 shRNA reduced G1 population of human pancreatic cancer cells 
compared with the cells transfected with scramble shRNA[5] . Moreover, a 
small-molecule Pim-3 kinase inhibitor markedly retarded in vitro growth of human 
pancreatic cancer cell lines by inducing G2/M arrest[66] , suggesting a potential role for 
Pim-3 in cell cycle progression. Consistently, cell cycle progression is accelerated in 
hepatocytes of transgenic mice, which express human Pim-3 cDNA selectively in 
hepatocytes[67]  and downregulation of Pim-3 decreased the amounts of Cdc25C, cyclin 
B1, and phospho-p21 (Our unpublished data). Thus, Pim-3 can promote cell cycle 
progression and eventually contribute to carcinogenesis by modulating the functions of 
these regulatory molecules involved in cell cycle progression. 
Mice deficient in all three Pim kinases are designated as triple knockout (TKO) 
mice. TKO mice have reduced body size at birth and throughout the postnatal period of 
their life and they are viable and fertile [68]. However, TKO mouse-derived embryonic 
fibroblasts (MEFs) show depressed AMP-dependent protein kinase (AMPK) activity, 
grow slowly in culture medium, and have decreased rates of 5′-cap-dependent protein 
synthesis [69]. Transduction of Pim-3 gene alone into these MEFs can reverse AMPK 
activation, increase protein synthesis, and drive the growth to a similar level as wild-type 
MEFs. Moreover, Pim-3 expression can markedly increase the levels of c-Myc and the 
peroxisome proliferation-activated receptor γ co-activator 1α (PGC-1α), enzymes 
capable of regulating glycolysis and mitochondrial biogenesis [69]. Similarly, Pim-1 and 
Pim-2 phosphorylate serine and threonine residues of c-Myc protein [55]. Furthermore, 
Pim-1 can act as a co-activator of Myc by phosphorylating Ser10 of histone H3 on the 
nucleosome at the Myc-binding sites [70]. Thus, Pim-3 can augment the rate of protein 
synthesis by modulating AMPK, c-Myc and PGC-1α (Figure 2). 
Li 11 
Pim-1 and Pim-3 together play a significant role in maintaining the self-renewal 
capacity of mouse embryonic stem (ES) cells in vitro [33]. ES cells overexpressing Pim-1 
and Pim-3 have a greater capacity to self-renew and display a greater resistance to LIF 
deprivation as evidenced by a clonal assay. On the contrary, ablation of Pim-1 and Pim-3 
genes increases the rate of spontaneous differentiation in a self-renewal assay and 
impairs the growth of undifferentiated ES cell colonies with increased rate of apoptosis 
[33]. 
Pim-3 is highly expressed at the cellular lamellipodia in endothelial cells and is 
co-localized with focal adhesion kinase (FAK). In addition, Pim-3 shRNA treatment 
impairs endothelial cell spreading, migration, and proliferation, leading to a reduction in 
tube-like structure development in a Matrigel assay [23]. However, TKO mice did not 
display any apparent abnormal phenotypes in embryogenesis and vascular development 
[68]. 
Pim-3 expression is detected in the β cells located in the pancreatic islets [71]. 
Pim-3-deficient mice exhibit an increased glucose tolerance and insulin sensitivity. 
Moreover, Pim-3 can negatively regulate insulin secretion by inhibiting the activation of 
Erk1/2 via SOCS6 [71]. In contrast, the inhibition of another survival kinase, Akt, can 
induce hyperglycemia [72, 73]. 
The switch from latent phase to productive viral reactivation (lytic phase) is 
crucial for sustaining viral multiplication in infected host cells. Findings from recent 
clinico-epidemiological study indicated the importance of lytic reactivation in the 
development and progression of Kaposi’s sarcoma (KS) [74]. Latency-associated nuclear 
antigen (LANA) is presumed to be a novel regulator of the life cycle of γ herpes virus 
including Kaposi’s sarcoma herpes virus (KSHV). Pim-1 and Pim-3 contribute to the 
viral reactivation of KSHV by phosphorylating LANA, and thereby promote KS 
progression [74]. 
 
5. Roles of Pim-3 in cancer development and progression, particularly in pancreas 
Pim-3 can contribute to cancer development and progression by acting on tumor 
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cells and tumor microenvironments. The primary activities of Pim-3 on tumor cells 
include the delivery of survival signaling, the regulation of cell cycle progression, 
protein synthesis, and Myc activation (Figure 3). In addition to its effects on tumor cells, 
Pim-3 can have profound impacts on tumor microenvironments, especially 
neovascularization process (Figure 3). In the following sections, we will discuss the roles 
of Pim-3 in carcinogenesis, with a focus on these two aspects. 
 
5.1. Effects of Pim-3 on tumor cells 
Forced expression of Pim-3 can promote anchorage-independent growth whereas 
co-expression of a kinase-dead Pim-3 mutant can attenuate EWS/FLI-mediated NIH 3T3 
tumorigenesis in immunodeficient mice [27]. These observations suggest the involvement 
of Pim-3 in cancer development and progression. 
Pim-3 can prevent apoptosis in pancreatic cancer cells by phosphorylating Bad a 
pro-apoptotic molecule on the serine residues (Ser112, Ser136, or Ser155), which in turn 
prevents Bcl-XL binding and promotes Bad translocation from the surface of the 
mitochondria to the cytosol by the protein 14-3-3 [48, 49]. Among the serine residues 
present in Bad, Ser112, but not Ser136 and Ser155, is abundantly phosphorylated in human 
pancreatic cancer cell lines. Moreover, the ablation of endogenous Pim-3 reduces the 
population of phosphorylated Bad followed by an enhancement of apoptosis, whereas 
Pim-3 overexpression produces exactly the opposite phenotypes. These observations 
suggest that Pim-3 has a crucial role in preventing apoptosis of human pancreatic cancer 
cells. 
Cell survival can be regulated by Wnt/β-catenin and Stat3 signaling pathways. An 
integrative molecular screening by using siRNA identified Pim-3 as a new regulator of  
Wnt/β-catenin signaling[75] . Thus, Pim-3 can positively regulate the Wnt/β-catenin 
signaling pathway in the colorectal cancer cell lines (DLD-1 and SW480) [75] . Moreover, 
Pim-3 is a positive regulator of Stat3 signaling in the prostate cancer cell line (DU-145) 
and in the pancreatic cancer derived cell line (MiaPaCa2) [56].  Thus, Pim-3 can promote 
cancer cell survival by modulating Wnt/β-catenin and/or Stat3 signaling pathways. 
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Pm-1 can promote cell cycle progression by phosphorylating and modulating the 
functions of molecules involved in cell cycle progression. Moreover, Pim kinases 
positively regulate transcription factors controlling the expression of genes implicated in 
cell cycle progression [65]. Since Pim-3 shares a high sequence identity with Pim-1, it is 
possible that Pim-3 can perform similar regulatory functions as Pim-1. Treatment with 
Pim-3 shRNA showed a marked reduction in G1 population of human pancreatic cancer 
cells while scramble shRNA had few effects [5]. Furthermore, a small-molecule Pim-3 
kinase inhibitor markedly retarded the in vitro growth of human pancreatic cancer cell 
lines by inducing G2/M arrest [66]. These findings indicate that Pim-3 may have a major 
influence in cell cycle progression of cancer cells. 
Pim-1 and Pim-2 help in cell survival by suppressing myc-induced apoptosis [10, 
11]. Transgenic mice expressing Eµ( immunoglobulin heavy-chain enhancer)-Pim-1 and 
Eµ-Myc succumb to lymphoma in utero or around birth [76]. On the contrary, Eµ-Myc 
transgenic mice that are deficient in Pim-1 and Pim-2 genes develop lymphoma slowly 
with time [8]. Thus, Myc-driven tumorigenesis depends on physiological levels of Pim-1 
and Pim-2 expression. Several mechanisms have been proposed to explain the 
cooperation between Myc and Pim kinases. Myc recruits Pim-1 to the E-boxes of the 
Myc target genes such as Fos-related antigen 1(FOSL1 (Fra-1)) and DNA-binding 
protein inhibitor ID2, and Pim-1 phosphorylates Ser10 of histone H3 on the nucleosome 
at the Myc-binding sites thereby, acting as a co-activator of Myc [70]. An expression 
profile analysis demonstrated that about 20 % of the Myc-regulated genes are also under 
the control of Pim-1 [70]. Moreover, Pim-1 and Pim-2 phosphorylate c-Myc protein at its 
serine and threonine residues [55]. This results in stabilization and subsequent 
enhancement of the transcription activities of c-Myc protein. Furthermore, Pim-3 can 
enhance c-Myc mRNA expression through the activation of PGC-1α [69]. The enhanced 
expression of c-Myc and PGC-1α may account for enhanced glycolysis. Thus, Pim 
kinases can promote tumorigenesis by modulating the activities of c-Myc and promoting 
Warburg effects [10, 11]. 
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5.2 Roles of Pim-3 in tumor microenvironments 
One of the basic characteristic features of tumor tissues is the abundance of 
newly formed vasculature for supply of nutrients and oxygen to the growing tumor cells 
and elimination of metabolic wastes and carbon dioxide. Pim-3 is abundantly expressed 
at mRNA and protein levels at the cellular lamellipodia and is co-localized with FAK in 
endothelial cells [23]. Pim-3 shRNA treatment impaired endothelial cell spreading, 
migration, and proliferation, leading to a reduction in tube-like structure formation in a 
Matrigel assay [23]. Moreover, tumor necrosis factor (TNF)-α transiently increases Pim-3 
mRNA expression through TNF receptor-1 (TNFR1) pathway in endothelial cells (ECs) 
and eventually promotes EC spreading and migration [77]. Constitutive Pim-3 
overexpression in gastric cancer tissues can induce angiogenesis [30]. 
Tumor-associated neovasculature formation is regulated by various angiogenic 
factors. Notably, vascular endothelial growth factor (VEGF) has an important role in 
tumor-associated vasculature formation [78, 79]. Although most pancreatic cancer tissues 
are hypovascular, elevated levels of VEGF are sometimes detected in pancreatic cancer 
cells[80]. Earlier studies have demonstrated that Pim-3 overexpression was responsible for 
increased VEGF expression and the growth of pancreatic cancer in vivo in an orthotopic 
nude mouse model [81]. The lack of any vascular phenotypes in Pim-3-deficient mice 
indicates that Pim-3 is dispensable for normal vasculature formation. However, given 
distinctive gene expression profiles of tumor-associated endothelial cells (ECs) [82], 
Pim-3 may have distinct roles in the tumor-associated endothelial cells. 
 
6. Pharmacological characterization of Pim-3 Inhibitors 
It is obvious from our discussions that aberrant activation and expression of Pim 
kinases are associated with various types of cancer. Enhanced expression of Pim-2 kinase 
is detected in hematologic malignancies and prostate cancer. Additionally increased 
Pim-1 expression is observed in pancreatic cancer, squamous cell carcinoma, gastric 
cancer, colorectal cancer, hepatocellular carcinoma [83-85], bladder carcinoma [86], and 
liposarcoma [87]. In contrast, Pim-3 expression is selectively overexpressed in malignant 
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lesions of endoderm-derived organs such as the liver [13], pancreas [5], colon [29], and 
stomach [30]. Furthermore, lack of apparent phenotypes in TKO mice suggests that Pim 
kinases are dispensable for the maintenance of normal functions of vital organs. 
Collectively, Pim kinases can be good candidate molecules for targeted cancer therapy. 
Examples of Pim-1 inhibitors include an anti-Pim-1 antibody and a cell penetrating 
peptide, both of which suppresses tumor growth in vivo in xenograft mouse models 
transplanted with human cancer cell lines [88, 89]. 
The crystal structure of Pim-3 has not yet been reported. However, the crystal structure 
of Pim-1 and Pim-2 has been resolved and revealed the presence of a unique hinge region 
that connects the two lobes of the protein kinase domain [18-20]. As a result, ATP binds to 
Pim kinases in a fundamentally different way from how it binds to other protein kinases 
[18, 19]. Thus, it may be possible to design compounds, which will selectively inhibit Pim 
kinases but no other serine/threonine kinases [16]. 
Several independent research groups have developed small-molecule inhibitors 
against Pim kinases including flavonol quercetargetin [90], imidazole[1,2-b]pyridazines 
[91, 92], bezylindene-thiazolidine-2,4-dione [93-95], 3,5-disubstituted indole derivatives [96], 
pyrazolo[3,4-g]quinoxaline derivatives [97], 1,6-dihydropyrazolo[4,3-c]carbazoles and 
3,6-dihydropyrazolo[3,4-c]carbazole derivatives [98], and pyrrolo[2,3-a]carbazole and 
pyrrolo[2,3-g]indazole derivatives [99-101]. Among them, 
1,6-dihydropyrazolo[4,3-c]carbazoles, 3,6-dihydropyrazolo[3,4-c]carbazoles, and 
pyrrolo[2,3-g]indazoles can inhibit Pim-3 activities [98, 100]. In our previous studies we 
have demonstrated that derivatives of stemonamide synthetic intermediates can inhibit 
Pim-3 as well as Pim-1 and Pim-2 activities and can reduce tumor growth in vivo in 
mouse xenograft models using human pancreatic cancer cell line without causing major 
adverse side-effects [102, 103]. 
The substrates preferred by Pim-1 and Pim-3 [19] are very similar in identity. 
Therefore, designing of isoform specific inhibitors that will differentiate and 
preferentially bind to one Pim member over the other is extremely challenging. Indeed, 
pyrrolo[2,3-a]carbazole has low nano molar binding affinity for Pim-1 and Pim-3 kinases 
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but only weakly inhibits Pim-2 (IC50  for Pim-1, 0.57 + 0.04 µM; IC50  for Pim-2, > 10 
µM; IC50  for Pim-3, 0.04 + 0.01 µM) [104]. Similar pharmacological observations have 
been recorded with phenanthrene derivatives [77]. However, it will be interesting to find 
out if an inhibitor which specifically inhibits the action of one Pim member will provide 
any additional advantage over a multi-Pim kinase inhibitor. 
Akt, similar to Pim kinases can phosphorylate a similar set of substrates, such as 
Bad, thereby initiating the proliferation of cancer cells [105]. Akt is aberrantly activated in 
various types of tumors and Akt inhibitors have been extensively investigated [72]. An Akt 
inhibitor, “GSK690693,” has exhibited potent antitumor activity in pre-clinical trials on 
animals [105]. Akt is a key signaling protein and Akt-2 is directly involved in insulin 
receptor signaling pathway. Consequently, the genetic disruption of Akt kinase genes 
results in severe phenotypic changes, such as neonatal mortality, severe growth 
retardation and reduced brain size [106-108] and Akt-2 inhibition induces severe 
hyperglycemia [105]. The use of Akt inhibitors for anticancer treatment is seriously 
limited because of these shortcomings. In contrast, Pim kinases including Pim-3 are not 
involved in insulin receptor signaling pathway, and the inhibition of Pim kinases hardly 
shows any detrimental effects on normal glucose metabolism. Thus, Pim kinases are 
more effective molecular targets than Akt for targeted cancer therapy, and are particularly 
useful for treating pancreatic cancer which gets frequently complicated by 
hyperglycemia. 
 
7. Future Perspectives 
Pim-3 kinase is aberrantly expressed in malignant lesions but not in normal 
tissues of endoderm-derived organs such as liver, pancreas, colon, and stomach [5, 13, 29, 30], 
and contributes to tumorigenesis by inhibiting apoptosis of tumor cells and promoting 
cell cycle progression. Moreover, genetic deficiency of Pim-3 gene does not result in 
apparent changes in phenotypes, suggesting that Pim-3 may be physiologically 
dispensable. Unlike Akt kinases [72], Pim kinases are not involved in insulin receptor 
signaling pathway; therefore, the inhibition of Pim kinases has very little influence on 
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glucose metabolism. Indeed, inhibition of Pim-3 kinase activities slows the growth or 
even causes regression of pancreatic tumors in mice without causing hypoglycemia [66, 102, 
103]. Since Pim-3 kinase is constitutively active, once it is expressed aberrantly, inhibition 
of Pim-3 can be used for inhibiting cancer progression. Furthermore, there is 
accumulating evidence to suggest that Pim-3 plays a vital role in the interaction between 
tumor cells and their surrounding stroma. Further studies on these aspects will unravel 
the novel pathophysiological roles of Pim-3. Nevertheless, strategies to inhibit Pim-3 
activity warrant an intensive investigation for the discovery, and development of new 
targeted anti-cancer therapeutics. 
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Table 1. Increased expression patterns for Pim kinases in various types of 
malignancies  
Tumor subtype Pim-1 Pim-2 Pim-3 
Solid tumor    
Pancreatic cancer + ND + 
Colon carcinoma + ND + 
Gastric cancer + ND + 
Hepatocellular carcinoma + + + 
Prostate adenocarcinoma + + + 
Bladder carcinoma + ND ND 
Squamous cell carcinoma of head and neck + ND ND 
Nasopharyngeal carcinoma ND ND + 
Oral squamous cell carcinoma + ND ND 
Liposarcoma + ND ND 
Ewing’s sarcoma ND ND + 
Hematological malignancies    
Acute myeloid leukemia  ND +  ND 
B Cell chronic lymphocytic leukemia ND + ND 
Primary mediastinal large B cell lymphoma + ND ND 
Mantle cell lymphoma + + ND 
Diffuse large B cell lymphoma + + ND 
Burkitt’s lymphoma + ND ND 




Figure 1. Amino acid alignment of human Pim family proteins [13]. The amino acid 
sequences of human Pim family kinases are aligned and common residues shared with 
Pim-3 are highlighted. The box indicates the hinge region. Residues marked with white 
and red color are important for ATP binding and substrate selectivity, respectively. 
 
Figure 2. Presumed biological functions of Pim-3. Pim-3 can interact with various 
target molecules, and thereby regulates various biological pathways including apoptosis, 
cell cycle, protein synthesis, and transcription.  
 
Figure 3. Presumed roles of Pim-3 in pancreatic carcinogenesis. Pim-3 expression is 
regulated at transcriptional and post-transcriptional levels, by transcription factors such 
as Ets-1 and post-translational controllers such as TCTP respectively. Pim-3 kinase 
activation contributes to pancreatic carcinogenesis by inducing cell survival, cell cycle 
progression, gene transcription, protein synthesis in tumor cells, and angiogenesis. 
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1 MLLSKINSLA HL-RAAPCND LHATKLAPGK -EKEPLESQY QVGPLLGSGG 50 
1 MLTKPLQ--- ---- GPPAP PGTPTPPPGG KDREAFEAEY RLGPLLGKGG 50 
Pim-1 
Pim-2 
Pim-3 1 MLLSKFGSLA HLCGPGGVDH LPVKILQPAK ADKESFEKAY QVGAVLGSGG 50 
60 70 80 90 100 
51 FGSVYSGIRV SDNLPVAIKH VEKDRISDWG ELPNGTRVPM EVVLLKKVSS 100 
51 FGTVFAGHRL TDRLQVAIKV IPRNRVLGWS PLSDSVTCPL EVALLWKVGA 100 
51 FGTVYAGSRI ADGLPVAVKH VVKERVTEWG SL-GGATVPL EVVLLRKVGA 100 
110 120 130 140 150 
101 --GFSGVIRL LDWFERPDSF VLILERPEPV QDLFDFITER GALQEELARS 150 
101 GGGHPGVIRL LDWFETQEGF MLVLERPLPA QDLFDYITEK GPLGEGPSRC 150 
101 AGGARGVIRL LDWFERPDGF LLVLERPEPA QDLFDFITER GALDEPLARR 150 
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151 FFWQVLEAVR HCHNCGVLHR DIKDENILID LNRGELKLID FGSGALLKDT 200 
151 FFGQVVAAIQ HCHSRGVVHR DIKDENILID LRRGCAKLID FGSGALLHDE 200 
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